[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TR201903587T4 - Telomeraz aktivitesinin artırılması için bileşimler. - Google Patents

Telomeraz aktivitesinin artırılması için bileşimler. Download PDF

Info

Publication number
TR201903587T4
TR201903587T4 TR2019/03587T TR201903587T TR201903587T4 TR 201903587 T4 TR201903587 T4 TR 201903587T4 TR 2019/03587 T TR2019/03587 T TR 2019/03587T TR 201903587 T TR201903587 T TR 201903587T TR 201903587 T4 TR201903587 T4 TR 201903587T4
Authority
TR
Turkey
Prior art keywords
compositions
telomerase activity
cells
compounds
useful
Prior art date
Application number
TR2019/03587T
Other languages
English (en)
Inventor
Calvin Halrley B
Allison Chin C
Akama Tsutomu
Yuk-Yu Ip Nancy
D Yung-Hou Wong Ph
M David Miller-Martini Dr
Original Assignee
Telomerase Activation Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telomerase Activation Sciences Inc filed Critical Telomerase Activation Sciences Inc
Publication of TR201903587T4 publication Critical patent/TR201903587T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)

Abstract

Mevcut buluş hücrelerde telomeraz aktivitesinin artırılması için yöntemler ve bileşimler ile ilgilidir. Bu tür bileşimler, topikal dahil farmasötik bileşimleri, ve nutrasötik bileşimleri içerir. Yöntemler ve bileşimler, bir hastanın hücresinde veya dokusunda telomeraz aktivitesindeki bir artış ile tedaviye tabi, örneğin, HIV enfeksiyonu, çeşitli dejeneratif hastalıklar, ve akut ve kronik deri rahatsızlıkları gibi hastalıkların tedavi edilmesinde faydalıdır. Bunlar, aynı zamanda, ex vivo hücre terapisi ve kök hücrelerin proliferasyonları gibi, kültür içerisindeki hücrelerin replikasyon kapasitesinin artırılmasında faydalıdır.
TR2019/03587T 2003-06-23 2004-06-23 Telomeraz aktivitesinin artırılması için bileşimler. TR201903587T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48098803P 2003-06-23 2003-06-23

Publications (1)

Publication Number Publication Date
TR201903587T4 true TR201903587T4 (tr) 2019-04-22

Family

ID=33551962

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2019/03587T TR201903587T4 (tr) 2003-06-23 2004-06-23 Telomeraz aktivitesinin artırılması için bileşimler.
TR2018/02543T TR201802543T4 (tr) 2003-06-23 2004-06-23 Telomeraz aktivitesinin artırılması ve hıv enfeksiyonunun tedavi edilmesi için bileşimler.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2018/02543T TR201802543T4 (tr) 2003-06-23 2004-06-23 Telomeraz aktivitesinin artırılması ve hıv enfeksiyonunun tedavi edilmesi için bileşimler.

Country Status (24)

Country Link
US (3) US7846904B2 (tr)
EP (2) EP1644009B1 (tr)
JP (4) JP5583882B2 (tr)
KR (3) KR101465515B1 (tr)
CN (1) CN1809364B (tr)
AP (1) AP2280A (tr)
AU (2) AU2004251753C1 (tr)
BR (1) BRPI0411856A (tr)
CA (1) CA2528483C (tr)
CY (2) CY1119951T1 (tr)
DK (2) DK1644009T3 (tr)
EA (1) EA009442B1 (tr)
ES (2) ES2716528T3 (tr)
HR (2) HRP20180330T1 (tr)
HU (2) HUE043168T2 (tr)
LT (2) LT2548880T (tr)
MX (1) MXPA05013844A (tr)
NZ (1) NZ544191A (tr)
PL (2) PL2548880T3 (tr)
PT (2) PT2548880T (tr)
SI (2) SI1644009T1 (tr)
TR (2) TR201903587T4 (tr)
WO (1) WO2005000245A2 (tr)
ZA (1) ZA200509846B (tr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
EP1644009B1 (en) * 2003-06-23 2017-11-29 Telomerase Activation Sciences, Inc. Compositions for increasing telomerase activity and treating hiv infection
WO2005000248A2 (en) * 2003-06-25 2005-01-06 Geron Corporation Compositions and methods for skin conditioning
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US8197860B2 (en) * 2005-06-23 2012-06-12 Nuliv Holding Inc. Method for enhancing nutrient absorption with astragalosides
CN100333731C (zh) * 2005-09-08 2007-08-29 南京医科大学 黄芪甲苷在制备治疗糖尿病周围神经病变药物中的应用
CN100384830C (zh) * 2006-01-12 2008-04-30 天津药物研究院 环黄芪醇类衍生物以及用途
US7992749B2 (en) 2006-03-30 2011-08-09 Nike, Inc. Support element for a carry strap
TR201819789T4 (tr) 2006-10-30 2019-01-21 Geron Corp Kanser tedavisine yönelik gemsitabin ve kombine telomeraz inhibitörü.
EP2152663B1 (en) 2007-06-04 2014-03-19 Ben Gurion University of the Negev Research and Development Authority Tri-aryl compounds and compositions comprising the same
CN101225424B (zh) * 2007-09-13 2013-05-29 天津药物研究院 环黄芪醇的单葡萄糖苷、其制备方法、药物组合物和应用
US8168596B2 (en) * 2008-10-17 2012-05-01 Nuliv Holding Inc. Use of cycloartane compounds for treating arthritis
SI2437606T1 (sl) * 2009-05-18 2016-10-28 Telomerase Activation Sciences, Inc. Sestavki in postopki za povečanje telomerazne aktivnosti
CA2912698A1 (en) * 2013-05-15 2014-11-20 Fybrands Corp. Compositions for improving the hair, skin, and nails
CR20160207A (es) 2013-11-05 2016-08-10 Ben Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad
CN104435370A (zh) * 2014-12-06 2015-03-25 王香平 风湿保健酒
CN104491185A (zh) * 2014-12-06 2015-04-08 郭亮 一种祛风湿药酒及其制备方法
CN104435371A (zh) * 2014-12-06 2015-03-25 郭亮 一种用于治疗关节炎的药酒
KR20160069857A (ko) 2014-12-09 2016-06-17 (주)스피어테크 텔로미어 활성을 증가시키기 위한 조성물 및 그 조성물의 제조방법
CN104817610A (zh) * 2015-03-15 2015-08-05 北京化工大学 利用硫酸水解制备环黄芪醇的方法
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
EP3277799B1 (en) 2015-04-03 2020-09-23 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN106474094A (zh) * 2015-08-31 2017-03-08 南京理工大学 一种环黄芪醇电纺纤维膜及其制备方法
US10066201B2 (en) 2015-09-11 2018-09-04 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN106307522A (zh) * 2016-11-06 2017-01-11 谭淞文 一种抗衰老保健品及其制备方法和食用方法
CN106831927B (zh) * 2017-02-07 2018-02-09 江西师范大学 一种黄芪甲苷的合成方法
CN108498521B (zh) * 2017-02-24 2020-05-05 北京大学 环黄芪醇在制备抑制腹主动脉瘤的药物中的应用
US10098922B1 (en) 2017-11-30 2018-10-16 Optigenex, Inc. Increasing telomere length in a cell
CA3145888A1 (en) * 2018-07-31 2020-02-06 Isilay KAVADARLI Ophthalmic formulations and uses thereof
CN111053782B (zh) 2018-10-17 2024-07-05 株式会社爱茉莉太平洋 包含人参皂苷的组合物
KR102635196B1 (ko) 2018-10-17 2024-02-13 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 미백 조성물
US11000538B2 (en) 2018-10-31 2021-05-11 Amorepacific Corporation Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside
WO2020131058A1 (en) * 2018-12-20 2020-06-25 Muhammed Majeed Telomerase enhancement potential of ecdysterone
CN109942663B (zh) * 2019-04-22 2021-10-26 中国人民解放军联勤保障部队第九八九医院 利用双相酸水解制备环黄芪醇的方法
MX2019006749A (es) 2019-06-10 2022-11-28 Univ Mexico Nac Autonoma Compuestos activadores de senescencia celular.
KR20210037257A (ko) 2019-09-27 2021-04-06 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 피부 탄력 개선용 조성물
KR20210037256A (ko) 2019-09-27 2021-04-06 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 갱년기 증상의 예방 또는 개선용 조성물
CN111419854B (zh) * 2020-05-18 2021-03-30 南通大学 具有特殊七元环结构的三萜在制备预防和治疗神经损伤药物中的应用
CN113480628B (zh) * 2021-08-17 2022-06-21 贵州师范大学 一种贵州疣螈多肽tk-cath及其编码基因和应用
CN113968894B (zh) * 2021-11-05 2024-05-28 山西大学 一种用黄芪甲苷降解制备环黄芪醇的方法
KR102666469B1 (ko) * 2023-05-04 2024-05-17 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6212791A (ja) 1986-07-18 1987-01-21 Osaka Chem Lab オウギサポニン、その単離法およびその用途
JPS6212792A (ja) * 1986-07-18 1987-01-21 Osaka Chem Lab オウギサポニン類の単離法
IT1259645B (it) 1992-04-10 1996-03-25 Solis Srl Metodo per la rivelazione della variazione di densita' di un tessuto e dispositivo per la sua attuazione
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US6007989A (en) 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
FR2695561B1 (fr) 1992-09-17 1994-12-02 Lvmh Rech Gie Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux.
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
JPH07238026A (ja) * 1994-02-25 1995-09-12 Pola Chem Ind Inc 動脈硬化抑制剤及びこれを含む食品又は医薬
AT402890B (de) 1994-03-16 1997-09-25 Berbi Gmbh Verwendung von notoginsenosid r1 zur herstellung von arzneimitteln
EP1293565A3 (en) * 1994-07-07 2004-05-12 Geron Corporation Mammalian telomerase RNA component
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US6162459A (en) 1995-02-24 2000-12-19 National Science Council Acyclovir transdermal delivery system
AUPN411195A0 (en) 1995-07-10 1995-08-03 Cathay Herbal Laboratories Pty Ltd Medicinal composition
CN1079265C (zh) 1995-08-01 2002-02-20 裴国增 灵芝口服液及其配制方法
US5785977A (en) 1996-02-07 1998-07-28 Breithbarth; Richard Non-metallic microparticle carrier materials
US5916565A (en) 1996-03-08 1999-06-29 In Clover, Inc. Product and method for treating joint disorders in vertebrates
TW452494B (en) 1996-03-12 2001-09-01 Jang De Shan Herbal composition for stimulating blood circulation
US5900226A (en) 1997-04-09 1999-05-04 Uop Llc Drying agents for non-foamed polyurethanes
JPH1036388A (ja) * 1996-07-25 1998-02-10 Kureha Chem Ind Co Ltd ジンセノサイド類含有ｈｓｐ４７合成抑制剤
DE841396T1 (de) 1996-10-01 1998-09-24 Geron Corp Katalytische Untereinheit der menschlichen Telomerase
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
PT988044E (pt) 1997-01-28 2008-04-07 Frank D Amelio Extracto de planta centipeda cunninghamii em água/etanol
US5786343A (en) 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
EP1011629B1 (en) 1997-09-05 2012-03-21 The Procter & Gamble Company Cleansing and conditioning products for skin or hair with improved deposition of conditioning ingredients
WO1999013861A1 (en) 1997-09-12 1999-03-25 The Procter & Gamble Company Cleansing and conditioning article for skin or hair
CA2315265A1 (en) 1998-01-12 1999-07-15 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
GB9815177D0 (en) 1998-07-13 1998-09-09 King S College London Treatment of skin disorders
WO2000008135A1 (en) 1998-08-09 2000-02-17 Board Of Regents, The University Of Texas System Methods and compositions for inhibiting or stimulating telomerase assembly
AU2156600A (en) 1998-11-25 2000-06-13 Cold Spring Harbor Laboratory Methods and reagents for increasing proliferative capacity and preventing replicative senescence
JP2000204091A (ja) * 1999-01-13 2000-07-25 Nippon Suisan Kaisha Ltd 新規ベンゾジオキソ―ル誘導体
JP2000229827A (ja) * 1999-02-05 2000-08-22 Kose Corp 皮膚外用剤
JP2000229834A (ja) * 1999-02-10 2000-08-22 Kanebo Ltd 化粧料
AUPQ127399A0 (en) * 1999-06-29 1999-07-22 Guangzhou University Of Traditional Chinese Medicine Compositions and methods for treating or preventing osteoporosis
IL148304A0 (en) 1999-09-10 2002-09-12 Geron Corp Oligonucleotide n3'-p5' thiophosphoramidates, their synthesis and use
JP2001258505A (ja) * 2000-03-24 2001-09-25 Fancl Corp 食品組成物
CA2307393A1 (en) * 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US6277396B1 (en) 2000-05-11 2001-08-21 Maximum Human Performance, Inc. Dietary supplement containing a thermogenic substance and an adrenal support substance
WO2001092289A1 (fr) 2000-05-31 2001-12-06 Japan Science And Technology Corporation Promoteurs de regeneration de tissu cutane contenant le ginsenoside rb1
CN1172677C (zh) 2000-07-14 2004-10-27 复旦大学附属中山医院 黄芪甲苷在制备药物组合物中的应用
GB0105613D0 (en) 2001-03-07 2001-04-25 Univ Cambridge Tech Pharmaceutically effective compounds and their use
WO2002007732A2 (en) 2000-07-26 2002-01-31 Cambridge University Technical Services Limited Use of panaxatriol for stimulation angiogenesis
US6696094B2 (en) 2000-10-18 2004-02-24 Tzu-Sheng Wu Herbal pharmaceutical composition for treatment of HIV/AIDS patients
CN1242807C (zh) * 2000-11-08 2006-02-22 天津市延龄营养保健品有限公司 一种抗皮肤过敏的药物组合物及其制法和用途
CN1369276A (zh) 2001-02-12 2002-09-18 徐秀荣 有效减轻体重的组合物和方法
JP2002275086A (ja) * 2001-03-15 2002-09-25 Fancl Corp 虚弱体質改善用組成物
US7262174B2 (en) 2001-05-09 2007-08-28 Geron Corporation Treatment for wounds
US20020182272A1 (en) 2001-05-30 2002-12-05 Bruce Halstead Methods of treatment of HIV-associated conditions
JP2003089687A (ja) * 2001-07-03 2003-03-28 Tanabe Seiyaku Co Ltd 新規ブタジエン誘導体、その製法およびその合成中間体
US20040180938A1 (en) 2001-07-03 2004-09-16 Akio Ohtani Novel butadiene derivatives, process for preparation of the same and intermediates for the synthesis thereof
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US20030108629A1 (en) 2001-07-17 2003-06-12 Chou Wen Hsien Compositions and methods for prostate and kidney health and disorders, an herbal preparation
CN1164608C (zh) * 2001-08-31 2004-09-01 上海中医药大学 具有抗心肌纤维化作用的黄芪皂甙甲
CN1406585A (zh) * 2001-09-07 2003-04-02 中国科学院上海药物研究所 一种治疗病毒性心肌炎的药物组合物
JP2003160497A (ja) * 2001-11-22 2003-06-03 Toshin Kagaku Kk 皮膚外用剤
WO2003066814A2 (en) 2002-02-04 2003-08-14 Ceremedix, Inc. Peptide-dependent upregulation of telomerase expression
CN1236803C (zh) 2002-03-20 2006-01-18 郑国芃 一种治疗风湿症的中药
CN1189176C (zh) * 2002-07-22 2005-02-16 江苏正大天晴药业股份有限公司 黄芪甲甙组合物及其制备方法
AU2003228378A1 (en) * 2003-03-26 2004-11-23 Westlake Partners Herbal compositions and methods for effecting weight loss in humans
EP1643946A2 (en) * 2003-06-20 2006-04-12 Viral Genomix, Inc. Compositions for and methods for treating hiv
EP1644009B1 (en) 2003-06-23 2017-11-29 Telomerase Activation Sciences, Inc. Compositions for increasing telomerase activity and treating hiv infection
WO2005000248A2 (en) 2003-06-25 2005-01-06 Geron Corporation Compositions and methods for skin conditioning
US20070122501A1 (en) 2003-06-27 2007-05-31 Hong Kong University Of Science And Technology Formulations containing astragalus extracts and uses thereof

Also Published As

Publication number Publication date
HUE036559T2 (hu) 2018-07-30
PT2548880T (pt) 2019-02-27
AU2004251753A1 (en) 2005-01-06
US20080113925A1 (en) 2008-05-15
SI2548880T1 (sl) 2019-04-30
JP5841337B2 (ja) 2016-01-13
ES2666864T3 (es) 2018-05-08
ES2716528T3 (es) 2019-06-13
AP2005003474A0 (en) 2005-12-31
MXPA05013844A (es) 2006-07-06
KR101312389B1 (ko) 2013-09-27
HRP20190322T1 (hr) 2019-04-19
JP2014024861A (ja) 2014-02-06
HRP20180330T1 (hr) 2018-04-20
CN1809364B (zh) 2010-06-16
EA009442B1 (ru) 2007-12-28
JP5583882B2 (ja) 2014-09-03
PL1644009T3 (pl) 2018-07-31
US7846904B2 (en) 2010-12-07
KR20110089887A (ko) 2011-08-09
TR201802543T4 (tr) 2018-03-21
KR20060034237A (ko) 2006-04-21
DK2548880T3 (en) 2019-04-08
DK1644009T3 (en) 2018-03-05
KR20130137252A (ko) 2013-12-16
US20110071095A1 (en) 2011-03-24
CY1121447T1 (el) 2020-05-29
LT1644009T (lt) 2018-03-12
EP2548880A3 (en) 2013-06-19
AP2280A (en) 2011-10-31
JP5913253B2 (ja) 2016-04-27
JP2011098991A (ja) 2011-05-19
SI1644009T1 (en) 2018-04-30
CY1119951T1 (el) 2018-12-12
EP1644009B1 (en) 2017-11-29
EP2548880A2 (en) 2013-01-23
WO2005000245A2 (en) 2005-01-06
AU2004251753B2 (en) 2008-11-20
CA2528483C (en) 2012-04-10
EP2548880B1 (en) 2019-01-09
PL2548880T3 (pl) 2019-07-31
ZA200509846B (en) 2007-04-25
JP2016041770A (ja) 2016-03-31
JP2007524627A (ja) 2007-08-30
LT2548880T (lt) 2019-03-25
CA2528483A1 (en) 2005-01-06
EP1644009A2 (en) 2006-04-12
WO2005000245A3 (en) 2005-05-26
NZ544191A (en) 2008-12-24
BRPI0411856A (pt) 2006-08-29
EP1644009A4 (en) 2010-04-07
CN1809364A (zh) 2006-07-26
AU2008249200A1 (en) 2008-12-18
PT1644009T (pt) 2018-02-28
EA200600076A1 (ru) 2006-08-25
US20150093455A1 (en) 2015-04-02
HUE043168T2 (hu) 2019-08-28
US8759304B2 (en) 2014-06-24
KR101465515B1 (ko) 2014-11-26
AU2004251753C1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
WO2005044179A3 (en) Formulations containing astragalus extracts and uses thereof
LTPA2016034I1 (lt) Brutono tirozinkinazės inhibitoriai
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
DE60302348D1 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
EP2298861A3 (en) Mesenchymal stem cells and uses therefor
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
ATE490470T1 (de) Therapieverfahren
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
BRPI0418157A (pt) terapêutica de tumores alogênicos
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
CY1108266T1 (el) Παραγωγα διβενζο(c) χρωμεν-6-ονης ως αντικαρκινικοι παραγοντες
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
MX2007004025A (es) Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._.
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
ATE441703T1 (de) Modifizierte humane mangan-superoxiddismutase und deren verwendungen
RU2006100561A (ru) Способ лечения онкологических забелеваний